Drugs / REGN5381
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05291546 | Apr 2022 → Apr 2024 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT04506645 | Sep 2020 → Dec 2022 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06833190 | Apr → Oct 2025 | hypertensive disorder | Regeneron Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT06237309 | Apr 2024 → Sep 2025 | heart failure | Regeneron Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT05353166 | Jun 2022 → Jun 2025 | heart failure | Regeneron Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN5381 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04506645 ↗ |
| Action | Activate | “REGN5381 (an NPR1 Agonist)” NCT04506645 ↗ |
| Modality | Protein / enzyme biologic | “an NPR1 Agonist Antibody” NCT05291546 ↗ |
| Route | Intravenous | “Single dose REGN5381 administered via IV infusion” NCT04506645 ↗ |
| Target | NPR1 | “REGN5381 (an NPR1 Agonist)” NCT04506645 ↗ |